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Abstract: After COVID-19, some patients develop long-term symptoms. Whether such symptoms
correlate with immune responses, and how long immunity persists, is not yet clear. This study
focused on mild COVID-19 and investigated correlations of immunity with persistent symptoms and
immune longevity. Persistent complications, including headache, concentration difficulties and loss
of smell/taste, were reported by 51 of 83 (61%) participants and decreased over time to 28% one year
after COVID-19. Specific IgA and IgG antibodies were detectable in 78% and 66% of participants,
respectively, at a 12-month follow-up. Median antibody levels decreased by approximately 50%
within the first 6 months but remained stable up to 12 months. Neutralizing antibodies could be
found in 50% of participants; specific INFgamma-producing T-cells were present in two thirds one
year after COVID-19. Activation-induced marker assays identified specific T-helper cells and central
memory T-cells in 80% of participants at a 12-month follow-up. In correlative analyses, older age and
a longer duration of the acute phase of COVID-19 were associated with higher humoral and T-cell
responses. A weak correlation between long-term loss of taste/smell and low IgA levels was found
at early time points. These data indicate a long-lasting immunological memory against SARS-CoV-2
after mild COVID-19.
Keywords: COVID-19; SARS-CoV-2; persistent symptoms; humoral immunity; cellular immunity
1. Introduction
Since the end of 2019, SARS-CoV-2 spread worldwide and caused a pandemic [1]. In
the acute phase of coronavirus disease 2019 (COVID-19), affected humans usually suffer
from mild symptoms similar to a flu-like infection; however, elderly people especially
also develop pneumonia, leading to sepsis with lethal outcomes [2,3]. In contrast to many
other viral infections, convalescents relatively often suffer from prolonged symptoms
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(“long COVID-19”). The most common symptoms are a persistent loss of taste and smell,
headaches, concentration disorders and fatigue [4]. Other complaints include respiratory
impairment, especially in patients with a severe COVID-19 course, and muscle or limb
pain [5]. These symptoms post-COVID-19 decrease in frequency over months after the
acute phase of infection [6], but how long they may persist, and whether they correlate
with specific immunity, is unclear up to now.
Another unanswered question is how long after COVID-19 does immunity protect
against re-infection. Some reports of recurrences of COVID-19 symptoms within weeks
of infection have been published, but these appear to be isolated cases [7]. Nevertheless,
it must be assumed that, especially in patients with asymptomatic or mild COVID-19, re-
infection is possible, due to the disappearance of specific anti-SARS-CoV-2 antibodies and
T-cells within a few months after primary infection. This could be prevented if individuals
are vaccinated before a critical drop in immunity occurs. Most published data of immune
memory against SARS-CoV-2 show a more or less consistent decrease in IgA, IgG and
neutralizing antibody levels as well as a decline of specific CD4+ and CD8+ cells within
the first 100 to 200 days after COVID-19 [8]. Up to now, it is not clear whether the loss
of humoral and cellular immunity is continuous or whether there is at least a gradual
stabilization of remaining antibodies and T-cells during the first year after COVID-19.
In this prospective study, we focused on COVID-19 patients with a mild course,
which is most common in adults at approximately 80% [9]. Such patients were questioned
regarding persisting symptoms or secondary disorders using a standardized questionnaire
one year after their acute disease. Additionally, humoral as well as cellular immunity
against SARS-CoV-2 were measured 6 and 12 months after COVID-19.
2. Materials and Methods
Convalescent plasma donors in the Institute for Transfusion Medicine, University
Hospital Augsburg, who experienced mild COVID-19 according to the WHO classifica-
tion [10], were prescreened for study inclusion. Data on medical history were obtained
from the plasma donor file. The study was approved by the ethical review board of
Ludwig-Maximilian-University of Munich. Signed informed consent was obtained from
all participants. Patients were included in the study after recovery from COVID-19. A first
analysis of humoral immunity against SARS-CoV-2 by IgA/IgG ELISA was carried out
as part of 6-week follow-up visit after onset of COVID-19 and repeated at a 6-month and
12-month follow-up, respectively. IgG and IgA antibodies directed against S1 protein were
analyzed using the in vitro SARS-CoV-2 ELISA assay (Euroimmun, Lübeck, Germany).
Test results are given as the ratio of binding of antibodies in tested plasma to that of a
calibrator (cut-off index values). A ratio > 1.1 indicates positive results.
Additionally, neutralizing antibodies (Nab) were measured at 6-week and 12-month
follow-up as described by Haselmann et al. [11]. SARS-CoV-2 (strain MUC IMB-1) was
cultured in Vero E6 cells. Virus stocks (50 TCID/50 µL) were prepared and stored at −80 ◦C
until further use. First, serum samples were diluted in 96-well culture plates (Greiner
bio-one, Frickenhausen, Germany) in Minimal Essential Medium (MEM, plus non-essential
amino acids solution and antibiotic–antimycotic solution; all Invitrogen, ThermoFisher
Scientific, Darmstadt, Germany) starting with a ratio of 1:5 up to a maximum of 1:640.
Virus was then added to each well and the serum–virus solution was incubated for one
hour at 37 ◦C (5% CO2). Afterwards, Vero E6 cells (1 × 104 cells/50 µL) were added to
each well and incubated for another 72 h at 37 ◦C (5% CO2). Then, the supernatants were
discarded and the wells were fixed in 13% formalin/PBS and stained with crystal violet.
Both known positive and negative serum samples were used as controls along with a mock
control and a back-titration of virus on each plate.
To capture cellular immunity against SARS-CoV-2, INFgamma (INFg)- and interleukin-2
(Il2)-ELISpot assays were used at 6- and 12-month follow-up. Ex vivo ELISpot/FLUOROspot
assays were performed using the Interferon-γ (IFNγ) and interleukin-2 (IL-2) CoV-iSpot
kit from Autoimmun Diagnostika (AID GmbH, Straßberg, Germany). Peripheral blood
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mononuclear cells (PBMC) from citrate blood drawn in the late afternoon were isolated the
following morning through Ficoll-Paque (GE Healthcare, Chicago, IL, USA), and seeded in
duplicate at a density of 2 × 105 cells per well in AIM-V medium. Cells were stimulated
for 18 h with the AID GmbH CoV-2 peptide library containing peptides from the S, N, M
and O proteins and CD28 antibody, or left unstimulated with CD28 antibody alone as a
negative control. As further controls to confirm specific responses to SARS CoV-2 peptides,
we stimulated cells in parallel with peptide libraries covering all coronaviruses (PAN),
as well as cytomegalovirus, Epstein–Barr virus and influenza viruses (CEF). Pokeweed
mitogen was used as a positive control. Spot numbers were counted using the AID
GmbH iSpot Reader. Samples were excluded if the pokeweed mitogen positive control
was less than 50 SFU/2 × 105 cells, or if the unstimulated control values were >10 or
>20 SFU/2 × 105 cells for IFNγ and IL-2, respectively. Positive responses were stringently
defined, essentially as described by AID GmbH, as samples that had a stimulation index of
≥7 for unstimulated control values ≤2 SFU/2 × 105 cells, and a stimulation index of >3 for
unstimulated control values >2 SFU/2 × 105 cells. We used a cohort of 32 seronegative
platelet donors as negative controls for the assay.
In addition, SARS-CoV-2-specific CD4+T-helper cells (THC, CD25hi CD134hi) were
identified using activation-induced marker (AIM) assays by flow cytometry as described
by Reiss et al. [12]. PBMC used in ELISpot assays were plated in round-bottom 96-well
plates at a density of 1 × 106/well in AIM-V medium, and incubated with medium alone as
an unstimulated control, or with the AID GmbH CoV-2 peptide library containing peptides
from the S, N, M and O proteins for 18 h. Cells were blocked with TruStain (BioLegend,
San Diego, CA, USA) for 30 min, before staining with CD4-Pacific Blue, CD134-FITC,
CD25-PEdazzle, CCR7-PerCP-Cy5.5, CD45RO-APC-Cy7, CXCR3-PE-Cy7 and CCR6-APC
(BioLegend) for 60min at 4oC. Cells were then washed with PBS and analyzed on a Cytoflex
S cytometer, with gating on live cells in the FSC/SSC gate, as shown in the gating strategy
(Figure 1). For analysis, both background subtracted (CD25hi CD134hi stimulated cells
minus CD25hi CD134hi unstimulated cells as % total CD4+T-cells) and stimulation indices
(CD25hi CD134hi stimulated cells divided by CD25hi CD134hi unstimulated cells as % total
CD4+T-cells, where any zero count values were set to the lower limit of 0.01% total CD4+T-
cells) were calculated. A stimulation index of greater than 2 indicated CoV-2-specific T-cells.
In participants with detectable specific THC, proportion of center memory cells (CD45RO+
CCR7+; Tcm), and effector memory cells (CD45RO+ CCR7-; Tem) were determined, and
the ratio of Tem to Tcm was calculated.
Long-term symptoms/secondary disorders were recorded by a structured question-
naire (Figure S1 in Supplementary Materials) from study participants at 12-month follow-
up. Pre-planned correlative analyses were preformed between humoral and cellular
immunity assays. Furthermore, the impact of participant’s age and gender, occurrence
of fever during acute infection and disease duration, as well as persistent symptoms to
performed antibody respective T-cell assays, were analyzed.
Statistics
Frequencies of persistent symptoms recorded from the questionnaire were calculated
for time periods of ≥1, 3, 6 and 12 months after onset of COVID-19. Wilcoxon test (two-
tailed) was used to detect significant differences in ELISpot stimulation indices and SARS-
CoV-2 antibody values, as well as for pre-planned correlative analyses. Correlations
between IgA/IgG antibody values and titer of neutralizing antibodies or T-cell response
were estimated by the Spearman test for non-normally distributed data.
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Figure 1. Flow cytometric gating strategy of AIM assay to identify specific T-helper cells (THC), and central memory T-
cell (Tcm) and effector memory T-cell (Tem) subsets from a participant included in the study: (A) lymphocytes (Gate P1) 
were gated using forward and side scatter; (B) gated on P1: THC (Gate P2) were defined by co-expression of CD3 and 
CD4; (D) gated on P2: specific THC (Gate P3) were analyzed as CD25 high/CD134 high double-positive cell population 
after stimulation with SARS-CoV-2; (C) borders of Gate P3 were defined by means of unstimulated THC population; (F) 
gated on P3: specific THC were further divided into Tcm and Tem; (E) borders between Tcm, Tem and naïve T-cells were 
defined by unstimulated THC. 
Figure 1. Flow cytometric gating strategy of AIM assay to identify specific T-helper cells (THC), and
central memory T-cell (Tcm) and effector memory T-cell (Tem) subsets from a participant included
in the study: (A) lymphocytes (Gate P1) were gated using forward and sid scat er; (B) gated on
P1: THC (Gate P2) were defined by co-expression of CD3 and CD4; (D) gated on P2: s ecific THC
(Gate P3) were analyzed as CD25 high/CD134 high double-positive cell population after stimulation
with SARS-CoV-2; (C) borders of Gate P3 were defined by means of unstimulated THC population;
(F) gated on P3: specific THC were further divided into Tcm and Tem; (E) borders between Tcm, Tem
and naïve T-cells were defined by unstimulated THC.
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3. Results
Of the 107 plasma donors approached, 83 included study participants attended all
three scheduled follow-up visits and were evaluable for the study. A consort diagram of
study participation is shown in Figure 2. Participant characteristics and data regarding the
acute phase of COVID-19 are shown in Table 1. Six participants were vaccinated before the
12-month follow-up (five at least 2 weeks before and one just 3 days before follow-up); no
participant was vaccinated at the 6-week or 6-month follow-up. At the 12-month follow-up,
the subgroup of five vaccinated participants (at least 2 weeks before follow-up) included two
females and three males with a median age of 27 years (range: 20–47), while the subgroup
of non-vaccinated participants contained 18 females and 59 males (age: 42 years (19–62)).
Table 1. Demographics and characteristics of 83 evaluable patients during acute COVID-19. * Homo-
geneous distribution across the years.
Demographics and Characteristics COVID-19 Patients
Age in years; median(range) 42 (19–62) *
Gender
male; n 63 (76%)
female; n 20 (24%)
Symptoms during acute COVID-19
fever (>38 ◦C); n 49 (59%)
cough; n 32 (39%)
loss of smell; n 25 (30%)
loss of taste; n 18 (22%)
headache; n 15 (18%)
dyspnoe; n 15 (18%)
myalgia; n 15 (18%)
sore throat; n 11 (13%)
pain of the joints; n 10 (12%)
rhinits; n 8 (9%)
diarrhoe; n 6 (7%)
nausea; n 1 (1%)
Duration of symptoms (days); median (range) 11 (1–35)
Patient’s care during acute COVID-19
non-hospitalization; n 80 (96%)
hospitalization; n 3 (4%)
Time period (days in median (range)) from
onset of COVID-19 to 6-week visit 37 (26–99)
onset of COVID-19 to 6-month visit 204 (184–280)




hay fever 4 (5%)
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3.1. Clinical Follow-Up
51 (61%) study participants complained of longer-lasting symptoms after the acute
infection symptoms had resolved, which decreased over time, but were still reported by
23 (28%) participants after one year. The most frequent complaints were loss of smell or
taste, concentration difficulties and headache. Disorders reported at lower frequencies
included dyspnea upon exertion and muscle, back or thoracic pain (Figure 3A, Table S1).
Most participants reported only one long-term complication, whereas loss of smell and
taste or back and muscle pain were reported also in combination (Figure 3B–E). Nine (11%)
study participants developed a cold or febrile infection, and new-onset disease of hair loss,
arterial hypertension and anal venous thrombosis affected one participant each.J. Clin. Med. 2021, 10, x FOR PEER REVIEW 7 of 14  
 
 
Figure 3. (A) Frequency of symptoms in patients after mild COVID-19 lasting at least 1, 3, 6 and 12 months, respectively, 
given in percentage. Correlation matrix displaying the co-occurrence of long-term symptoms for at least 1 (B), 3 (C), 6 (D) 
and 12 (E) months after COVID-19. Color intensity and the size of the circle are proportional to the correlation coefficients. 
Figure 3. (A) Frequency of symptoms in patients after mild COVID-19 lasting at least 1, 3, 6 and
12 mon hs, respectively, given in percentage. Correlati n matrix displaying th co-occurrence of
long-term symptoms for at least 1 (B), 3 (C), 6 (D) and 12 (E) months after COVID-19. Color intensity
and the size of the circle are proportional to the correlation coefficients.
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On the visual scale of the questionnaire, 56 (67%) participants reported a complete
restoration of resilience and fitness compared to the period before COVID-19 at the 12-
month follow-up. Minor limitations (scale-1) were reported by 16 participants (19%), and
mild (scale-2), moderate (scale-3) or severe limitations (scale-4) were reported by 5 (6%),
2 (2%), and 1(1%) participants, respectively. Three (3%) participants reported having a
better fitness than before COVID-19. No participant reported very severe limitations (scale-
5). The occurrence of persistent symptoms or impaired fitness did not correlate with age,
sex or fever during the acute phase of COVID-19.
3.2. Humoral Immunity
At the 6-week follow-up, a high proportion of participants had specific IgA and IgG
(76/83 (92%) and 79/83 (95%), respectively) antibodies, which decreased to 65/83 (78%)
and 58/83 (70%), respectively, at the 6-month follow-up, and further decreased to 60/77
(78%) and 55/77 (66%), respectively, at the 12-month follow-up (only non-vaccinated
participants were considered at the last visit). Median levels of IgA and IgG antibodies
decreased from 3.4 and 3.7, respectively, at 6 weeks, to 1.8 and 1.8 at 6 months, to 1.9
and 1.7 at 12 months (Table 2, Figure 4A,B for non-vaccinated patients). There were high
correlations between IgA and IgG at the 6-week (R2 linear = 0.313, correlation coefficient
(cc) = 0.545, p < 0.001), 6-month (R2 linear = 0.413, correlation coefficient (cc) = 0.640,
p < 0.001), and 12-month follow-up (R2 linear = 0.303, correlation coefficient (cc) = 0.592,
p < 0.001, non-vaccinated participants only, Figure 5A).




Figure 4. Course of IgA/IgG antibody level (A,B) and specific T-cells (C,D) over time. Black lines in 
boxplots represent median values. * p < 0.001 significant value. At 12-months measurement points, 
only non-vaccinated participants were considered. 
 
Figure 5. Correlation analyses of humoral and cellular immunity assays in non-vaccinated participants at 12-months 
follow-up: (A) IgG value vs. IgA value; (B) titer of Nab vs. IgA value; (C) titer of Nab vs. IgG value; (D) INFg+ T-cells vs. 
specific THC; (E) IgG value vs. specific THC; (F) titer of Nab vs. specific THC; Nab, neutralizing antibody; THC, T-helper 
cells; SI, stimulation index. 
Figure 4. Course of IgA/IgG antibody level (A,B) and specific T-cells (C,D) over time. Black lines in
boxplots represent median values. * p < 0.001 significant value. At 12-months measurement points,
only non-vaccinated participants were considered.
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Table 2. Analysis of humoral immunity against SARS-CoV-2 at 6-week and 6-month follow-up (all participants non-
vaccinated) as well as at 12-month follow-up grouped between vaccinated and non-vaccinated participants. Results are
given as median values (range): Nab, neutralizing antibodies; *, at least 14 days before 12 months follow-up visit; p1 value,
6-week vs. 6-month; p2 value, vaccinated * vs. non-vaccinated at 12-months visit.






(Non-Vaccinated, n = 77)
12-Month Visit
(Vaccinated *, n = 5)
p2
Value
IgA value 3.38 (0.8–11.0) 1.80 (0.4–9.0) <0.001 1.9 (0.5–20.3) 22.3 (10.3–22.3) <0.001
IgG value 3.65 (0.5–15.8) 1.80 (0.2–7.5) <0.001 1.7 (0.6–10.6) 35.0 (13.1–40.8) <0.001
Nab titer 1:5 (1:1–1:640) not done 1:1 (1:1–1:40) 1:320 (1:160–1:320) <0.001
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Figure 5. Correlation analyses of l ll lar i munity assays in non-vaccinated participants at 12-months
follow-up: (A) IgG value vs. IgA value; (B) titer of Nab vs. IgA value; (C) titer of Nab vs. IgG value; (D) INFg+ T-cells vs.
specific THC; (E) IgG value vs. specific THC; (F) titer of Nab vs. specific THC; Nab, neutralizing antibody; THC, T-helper
cells; SI, stimulation index.
Neutralizing antibodies (titer of 1:5 or higher) could be detected in 66/83 (80%) partic-
ipants of the total study cohort at the 6-week follow-up, and in 37/77 (48%) non-vaccinated
participants at the 12-month follow-up. Nab correlated with IgA and IgG antibody levels
at both the 6-week (R2 linear = 0.202, cc = 0.457, p < 0.001 and R2 linear = 0.603, cc = 0.775,
p < 0.001, respectively) and 12-month follow-up (R2 linear = 0.163, cc = 0.432, p < 0.001 and
R2 linear = 0.541, cc = 0.742, p < 0.001, respectively, Figure 5B,C).
Vaccinated participants had very high median levels of IgA (22.3) and IgG (35.0)
values as well as Nab (1:320) at the 12-month follow-up (Table 2).
3.3. Cellular Immunity
Of the evaluable participants at the 6-month follow-up, 40/51 (78%) had T-cells that
produced INFg, and 24/32 (75%) had T-cells that produced IL-2, as measured by the
ELISpot assay. A lower proportion of non-vaccinated evaluable participants had T-cells
that produced INFg (48/76 (63%) and IL-2 (30/70 (43%)) at the 12-month follow-up. Only
one of the 32 CoV2-seronegative platelet donors (INFg: median: 0.5 SI (range: 0.0–12.0),
and Il-2: 2.5 SI (0.5–18.5)), which we used as negative controls for the assay, had a positive
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T-cell response, possibly due to T-cell cross-reactivity between coronaviruses as previously
described [13,14]. Values of stimulation indices are shown in Figure 4 and listed in Table 3.
Table 3. Analysis of cellular immunity against SARS-CoV-2 measured by AIM and ELISpot at 6- and 12-month follow-up.
Results are given as median values (range). # Values determined for participants with detectable specific T-helper cells
(THC) only; INFg, interferon gamma; Il-2, interleukin-2; SI, stimulation index; Tcm, central memory T-helper cells; Tem,
effector memory T-helper cells; *, Vaccination at least 14 days before; p1 value, 6-week vs. 6-month visit; p2 value, vaccinated
vs. non-vaccinated at 12-month visit.







Elispot INFg SI value n = 51 19.0 (2.5–179) n = 76 6.9 (0.0–93) <0.001 n = 5 22.5 (5.0–74) 0.032
Il-2 SI value n = 32 22.0 (4.0–485) n = 70 3.2 (0.7–29) <0.001 n = 5 4.5 (2.2–19) 0.206
Double positive SI n = 32 6.8 (0.0–74) n = 70 3.3 (0.0–29) 0.001 n = 5 2.5 (1.0–17) 0.781
AIM Specific THC (%) n = 70 0.08 (0.01–1.71) n = 5 0.1 (0.02–0.93) 0.845
THC SI value n = 70 5.1 (1.0–53) n = 5 10.0 (2.0–16) 0.462
specific Tcm (%) # n = 56 39 (8–64) n = 5 53 (23–100) 0.080
specific Tem (%) # n = 56 58 (20–84) n = 5 44 (1–67) 0.039
ratio Tem / Tcm # n = 56 1.5 (0.3–10.5) n = 5 0.8 (0.01–2.9) 0.059
Specific THC could be detected in 56/70 (80%) non-vaccinated evaluable participants
by the AIM assay at the 12-month follow-up. The THC population in non-vaccinated
participants contained 39% central memory T-cells and 58% effector memory T-cells with a
Tem/Tcm ratio of 1.5 (Table 3).
The proportions of THC measured by flow cytometry showed a high correlation
with the stimulation index values of the INFg Elispot assay (R2 linear = 0.252, cc = 0.420,
p < 0.001, Figure 5D).
3.4. Correlative Analyses
High correlations could be found between IgG antibody and neutralizing antibody
values with specific T-cells measured by INFg- and IL-2-ELISpot assays as well as THC
detected by the AIM assay (R2, cc and p-values are listed in Table S2, see also Figure 5E,F)
in non-vaccinated participants at the 12-month follow-up.
Sex of participants had an impact of median IgA antibody levels at the 6-week follow-
up, with lower values in females (1.8 (range: 0.9–10.0) vs. 3.6 (0.8–11.0); p = 0.005). This
sex-dependent difference was not seen at the 6-month or 12-month follow-up.
Age influenced cellular immunity measured at the 12-month follow-up. Older
(≥median age of 42 years) non-vaccinated participants had higher stimulation indices (SI)
in INFg- and IL-2-ELISpot assays (9.5 (range: 0.0–93) vs. 5.2 (1.9–53), p = 0.006, respec-
tively, (3.5 (0.7–25) vs. 2.5 (0.9–29), p = 0.031), as well as a higher SI in the double-positive
IFN+IL-2+ ELISpot assay (4.5 (range: 0.0–29) vs. 3.0 (0.0–12), p = 0.043). This difference
was also seen in the PAN control INFg Elispot assay (8.0 (1.0–68) vs. 4.6 (0.0–52), p = 0.014).
Furthermore, older participants had a higher proportion of specific THC in the AIM assay
(0.17% (0.01–1.71) vs. 0.06% (0.01–1.20, p = 0.003).
A longer duration of the acute phase of COVID-19 (>median duration of 10 days) was
associated with a higher IgG antibody level at the 6- and 12-month follow-up (2.7 (0.2–
6.3) vs. 1.3 (0.4–7.5), p = 0.043, and 3.3 (0.6–9.5) vs. 1.4 (0.6–10.6), p = 0.024, respectively;
non-vaccinated only). The duration of the acute phase of COVID-19 also correlated with
the SI of the double-positive IFNg+IL-2+ ELISpot assay (R2 linear = 0.170, cc = 0.265,
p = 0.027), with significantly more double-positive T-cells at the 12-month follow-up in
participants with a longer versus shorter acute phase of COVID-19 (12/31 (39%) vs. 3/39
(8%); p = 0.002).
Loss of smell or taste up to 3 months was associated with lower IgA levels as measured
at both the 6-week and 6-month follow-up (1.9 (0.8–9.7) vs. 3.6 (0.8–11), p = 0.016, and 1.4
(0.4–6.0) vs. 2.1 (0.4–9), p = 0.006, respectively) but not at the 12-month follow-up.
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All other participants’ demographics and characteristics, as well as long-term symp-
toms, did not influence humoral or cellular immunity in our study cohort.
4. Discussion
In this study, we report long-term clinical and immunological data from patients up to
one year after mild COVID-19. The proportion of participants complaining about persistent
symptoms decreased over time but was still surprisingly high at 28% after 12 months. We
found no correlations of specific immunity with long-term complications, apart from a
weak association of low IgA at early time points in patients with loss of taste and/or smell.
We show that the duration of acute infection correlates with humoral and T-cell immunity.
While most participants still have specific antibodies, only half have neutralizing antibodies
after 12 months. By contrast, around two-thirds of participants maintained IFNg+-specific
T-cell responses at the 12-month follow-up, and 80% of participants had specific T-helper
cells, including long-lived central memory T-cells, indicative of long-term T-cell immunity.
The most frequent long-term symptoms were neurological: most frequently the loss
of smell and/or taste followed by a headache and difficulties with concentration. This
finding is consistent with published data that also show that neurologic symptoms most
often persist [15]. In particular, a persistent loss of taste and smell are very commonly
associated [16], as also shown in our study.
The most common physical limitation was dyspnea upon exertion, which was still
persistent in 8% one year after COVID-19. This long-term complication after one year
is remarkable because all participants in our study had only a mild course of disease
and almost none were hospitalized. Such clinically relevant long-term complaints in out-
patients were also reported by other research groups [17], suggesting a lung involvement in
this patient cohort, even though this had not been diagnosed by imaging during the acute
phase of the disease. Within the first year after COVID-19, only 11% of participants reported
a cold or febrile infection, suggesting that SARS-CoV-2 infection does not cause long-term
immunodeficiency. The concern about immunodeficiency following COVID-19 is due
to the reduced lymphocyte count during the acute infection [18], as has been observed
in some other viral infections [19–21]. A low frequency of subsequent infections in our
cohort, together with follow-up data showing normal lymphocyte counts and normal
lymphocyte subset distribution one month after mild COVID-19, suggest that any possible
immunodeficiency would be short-lived [22]. Other persistent physical complaints or
new-onset conditions were rare and reported only in individual cases.
In order to capture the symptom of fatigue, which is not easy to detect by medical
history, study participants were asked about their restoration of resilience and fitness on
the visual scale of the questionnaire. Only two-thirds reported a completely restored health,
whereas one third still complained about restricted fitness one year after mild COVID-19.
Levels of IgA and IgG antibodies at the 6-month follow-up were approximately half
that of their assumed maximum value measured 6 weeks after disease onset [23], and
remained stable up to the 12-months follow-up, thereby showing a biphasic decrease as
previously described [24,25]. In contrast to IgM antibodies, IgG antibodies specifically
directed against the spike protein of SARS-CoV-2 persist relatively stable over time as
described by Dan JM et al., who found a percentage of 90% spike IgG-positive convalescents
half a year after COVID-19 [26]. However, similar antibody decreases with persistent sero-
positivity, as in our analysis in patients with mild or moderate COVID-19, have also been
reported by other investigators [27,28], but with somewhat shorter follow-ups of 7 and
4 months, respectively. Despite these pronounced decreasing antibody levels, humoral
immunity to SARS-CoV-2 was demonstrated in nearly 80% of participants in our study
participants at the 12-month follow-up. Neutralizing antibodies, which are often used as
biological markers of humoral protective immunity [29], also decreased from 80% 6 weeks
after infection to 50% one year later. A previous study similarly showed that health care
workers all developed Nab three weeks after a mild course of COVID-19, but 15% of those
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studied had lost detectable Nab [30] three months later, suggesting that they are at risk of
reinfection relatively soon after primary infection.
CoV-2-specific T-cells in the participants of our study showed a marked decrease in
T-cell responses measured by INFg-Elispot from 78% at 6 months post-infection to 63% at
12 months post-infection. There was also a significant decrease in the absolute levels of
IFNg and a strong decrease in IL-2 levels. Given that ELISpot predominantly measures
immediate responses from effector and effector memory T-cells, this assay may not be
suitable to measure the longevity of T-cell responses. For this reason, we additionally
used AIM assays to measure the total CD4+ helper, central memory and effector memory
T-cell responses. Specific T-helper cells were found in 80% of participants one year after
mild COVID-19, with prominent central memory T-cell components, indicating that the
majority of patients even with mild COVID-19 develop memory T-cell responses required
for long-term protection from severe disease [31]. This assumption is supported by an
observation from Wuhan, China, where the majority of COVID-19 patients also showed a
decrease in T-cells directed against SARS-CoV-2 in a biphasic manner. Comparable to our
study, the Chinese study found a loss of specific CD8 T-cells in 26% of convalescents and a
loss of specific CD4 helper cells in only 16% after 9 months [32].
Considering possible factors influencing specific immunity to SARS-CoV-2, we found
positive correlations between the duration of acute illness and the level of IgG antibodies, as
well as double-positive IFNg+IL-2+-specific T-cells, in our study. This indicates that patients
with a short term of COVID-19 probably have a higher risk to lose specific immunity against
SARS-CoV-2 within months. Age also had an impact, particularly on cellular immunity
with higher levels of specific T-cells in older participants than younger ones, as measured
by the AIM assay. Surprisingly, older participants responded significantly better to epitopes
cross-reactive across all coronaviruses (PAN library control) than younger participants,
suggesting that either older participants have more exposure to seasonal coronaviruses
over their lifetime, or, more likely, that the immune responses of older patients target a
broader repertoire of epitopes, a factor which is associated with control of infection [33].
Surprisingly, we found no correlations of increased specific humoral or cellular im-
munity with long-term complications. This is possibly because long-term complications
following COVID-19 are probably caused by virus-specific pathophysiological changes,
immunological dysregulation and inflammatory damage in response to the acute infection
but independent from acute immune defense against the virus, which determines specific
anti-SARS-CoV-2 antibody levels and T-cell counts [34]. Counter-intuitively, however, pa-
tients with persistent loss of smell or taste lasting at least 3 months had strikingly low levels
of specific IgA. IgA is mainly responsible for mucosal immunity as the major proportion of
neutralizing antibodies to SARS-CoV-2 in the early humoral immune response [28]. Given
the efficient evasion of innate immune responses by SARS-CoV-2 [35], these long-term
complications may not be due to an over-reactive immune response, but rather due to a
lack or delay of specific humoral immunity at a critical phase or site of infection.
Our study clearly has limitations. Although our study provides an estimate of common
long-term effects, it is not powered to detect rare complications, or new-onset disorders,
due to low participant numbers. On the other hand, we were able to utilize a far broader
range of assays in our smaller cohort than comparable studies for correlative analyses.
Another limitation is the sex imbalance in our study, with a clear preponderance of male
participants. This was due to the continuous inclusion of all patients with mild COVID-19
who had registered for a plasma donor and agreed to participate in the study without
considering sex.
5. Conclusions
Taken together, we find no correlation of immunological factors with the development
of long-term complications (long COVID) despite extensive immunological characterization
of patients with exclusively mild infection, with the exception of a weak correlation of
low IgA at early time points in participants that suffered loss of taste and smell. We
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show that antibody and T-cell responses correlate with the duration of infection, and
that these are comparably stable between 6 and 12 months post-infection. Nevertheless,
neutralizing antibodies were found in only 50% of participants at 12 months post-infection.
Similarly, there was a significant decrease in cellular immunity from 6 to 12 months post-
infection measured by ELISpot, even though 80% of participants developed measurable
CoV-2-specific CD4+T-cells indicative of long-term memory.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/jcm10153305/s1; Figure S1, structured questionnaire for follow-up after COVID-19; Table
S1, frequency of persistent symptoms after mild COVID-19 (total number: 83); Table S2, correlation
analysis between humoral and cellular immunity of non-vaccinated participants at 12-month follow-
up; THC, T-helper cells; Nab, neutralizing antibodies; SI, stimulation index.
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